← Back to Treatments
🏅 FDA Orphan Designation

Opdualag

nivolumab and relatlimab-rmbw

Manufacturer: Bristol-Myers Squibb Company

Indicated for:
NON RARE IN EUROPE: MelanomaOrphanConjunctival malignant melanoma

FDA-Approved Indications (2)

Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma

indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma

Population: adult and pediatric patients ≥12 years

Indications & Usage

1 INDICATIONS AND USAGE OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (1)

💙 Support Programs

View all →
Opdualag
Bristol-Myers Squibb Company
Apply ↗
OPDUALAG
Bristol Myers Squibb
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.